Jadelle

Manufactured by Bayer

Sourced in Finland

Jadelle is a contraceptive implant that contains two small, slender, flexible rods made of a plastic-like material. The rods are implanted under the skin of the upper arm and release a continuous, low dose of the progestogen hormone levonorgestrel to prevent pregnancy.

Automatically generated - may contain errors

Lab products found in correlation

Depo provera, by Pfizer (2 mentions)

5 protocols using jadelle

Contraceptive Methods and Weight Change

Check if the same lab product or an alternative is used in the 5 most similar protocols

At enrolment, women were randomly assigned (1:1:1) to the DMPA-IM group, Copper IUD group, or LNG implant group. Participants received a Cu IUD (Optima TCu380A; Injeflex, Sao Paolo, Brazil), an LNG implant (Jadelle; Bayer, Turku, Finland) or an injection of 150 mg/mL DMPA-IM (Depo Provera; Pfizer, Puurs, Belgium), which was provided on site at enrolment and for the DMPA-IM group at every 3-monthly follow-up visit up to 18 months.
Ethics review committees at each study site, FHI 360, and the World Health Organization (WHO) approved the study protocol. Women provided written informed consent in a language of their choice prior to the conduct of any study related procedures.
Outcomes: The primary outcome of this secondary analysis is weight change from study enrolment to the final visit at study month 12–18.

Beksinska M., Issema R., Beesham I., Lalbahadur T., Thomas K., Morrison C., Hofmeyr G.J., Steyn P.S., Mugo N., Palanee-Phillips T., Ahmed K., Nair G., Baeten J.M, & Smit J. (2021). Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial. EClinicalMedicine, 34, 100800.

+ Open protocol

+ Expand

Pharmacokinetics of LNG Implants in Ugandan Women on Efavirenz-based ART

Check if the same lab product or an alternative is used in the 5 most similar protocols

We conducted a non-randomized, open-label, longitudinal pharmacokinetic study to assess the safety and pharmacokinetics of 300mg LNG subdermal implants (2 × 2-rod 75mg LNG/rod; Jadelle^®; Bayer, New Zealand) among Ugandan women taking efavirenz-based ART (300LNG+ART group, n=27) [11 ]. We compared outcomes with a contemporaneous cohort of 19 adult Ugandan women without HIV and not on efavirenz-based ART receiving standard dose LNG implant (1 × 2-rod 75mg LNG/rod; 150LNG group) [12 (link)]. Investigators performed study-related procedures at the Infectious Diseases Institute (IDI), Makerere University College of Health Sciences, Kampala, Uganda, in accordance with the Declaration of Helsinki. Ethics boards at the Joint Clinical Research Centre Kampala, Uganda National Council for Science and Technology, and the University of Nebraska Medical Center approved all study procedures. All volunteers provided written informed consent. This study is registered in ClinicalTrials.gov (Identifier: NCT02722421).

Mello C.V., Vicario D.S, & Clayton D.F. (1992). Song presentation induces gene expression in the songbird forebrain.. Proceedings of the National Academy of Sciences of the United States of America, 89(15), 6818-6822.

+ Open protocol

+ Expand

Randomized Contraceptive Comparison Study

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

At enrolment, women were randomly assigned (1:1:1) to DMPA-IM, copper IUD or LNG implant.6 (link) Participants received an injection of 150 mg/mL DMPA-IM (Depo Provera; Pfizer, Puurs, Belgium) at enrolment and every 3 months until the final visit at 18 months after enrolment, a copper IUD (Optima TCu380A; Injeflex, Sao Paolo, Brazil) or a LNG implant (Jadelle; Bayer, Turku, Finland) at enrolment. Women returned for follow-up visits at 1 month after enrolment to address initial contraceptive side-effects and every 3 months thereafter, for up to 18 months with later enrolling participants contributing 12 to 18 months of follow-up. Visits included HIV serological testing, contraceptive counselling, syndromic STI management and safety monitoring.

Deese J., Philip N., Lind M., Ahmed K., Batting J., Beksinska M., Edward V.A., Louw C.E., Onono M., Palanee-Phillips T., Smit J.A., Baeten J.M., Donnell D., Mastro T.D., Mugo N.R., Nanda K., Rees H, & Morrison C. (2020). Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant. Sexually Transmitted Infections, 97(4), 249-255.

+ Open protocol

+ Expand

Comparison of Contraceptive Effectiveness

Check if the same lab product or an alternative is used in the 5 most similar protocols

DMPA IM 150 mg/1 ml (Depo Provera, Pfizer) is a 3-monthly progestogen-only injectable with a 0.2% failure rate with perfect use, but a 6% failure rate with typical use
¹⁸. The LNG implant (Jadelle, Bayer) consists of two silicone rods each containing 75 mg of LNG and is highly effective and user independent, with failure rates of <1% for both perfect and typical use
^{19 (link)}. The T-380A copper IUD, when inserted correctly, has failure rates of <1% in the first year, and only 2.2% in the first 10 years of use
^{20 (link)}. The contraceptive methods were purchased or donated by USAID or the South African government. The manufacturers were not involved in the design or execution of the trial.

Hofmeyr G.J., Morrison C.S., Baeten J.M., Chipato T., Donnell D., Gichangi P., Mugo N., Nanda K., Rees H., Steyn P, & Taylor D. (2018). Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study). Gates Open Research, 1, 17.

+ Open protocol

+ Expand

ECHO Contraceptive Effectiveness Trial

Check if the same lab product or an alternative is used in the 5 most similar protocols

Following online registration, the ECHO trial centrally randomized participating women to DMPA‐IM (150 mg/ml, Depot‐Provera^®; Pfizer, Puurs, Belgium) given intramuscularly every 12 weeks, insertion of the Copper IUD (Optima TCu380A^®; Injeflex, Sao Paolo, Brazil) at enrollment, or insertion of the subdermal LNG implant (150 mg, Jadelle^®; Bayer, Turku, Finland) at enrollment. Participant and personnel blinding was not possible because of the nature of the interventions, and participant follow up was conducted at 1, 3, 6, 9, 12, 15, and 18 months. ECHO participants at our site who additionally consented to participate in this ancillary study were enrolled at the 1‐month ECHO follow‐up visit, and were interviewed at the 3‐ and 12‐month visits for this purpose by trained research assistants. The 12‐month follow up was an extension of the protocol that had originally planned a 3‐month follow up only. Some participants (n = 53) only contributed data at the 12‐month visit.

Singata‐Madliki M., Carayon‐Lefebvre d’Hellencourt F., Lawrie T.A., Balakrishna Y, & Hofmeyr G.J. (2021). Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial. International Journal of Gynaecology and Obstetrics, 154(2), 256-262.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!